Wednesday 19 December 2018 ,
Wednesday 19 December 2018 ,
Latest News
  • AL to fulfill youth expectations: Hasina
  • 9 of a family burnt in Narayanganj fire
  • Saiful becomes JPC president, Farida retains GS post
  • AL to introduce 5G services, reduce cost of internet, cell-phone use
  • HC confirms Khaleda's ineligibility to contest polls
  • BNP manifesto promises scrapping black laws, higher GDP growth
  • Quader hopes AL to win next polls again
21 May, 2018 00:00 00 AM

FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

FDA
FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

The U.S. Food and Drug Administration recently approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.

“It is important for patients to have access to safe, effective and affordable biological products and we are committed to facilitating the development and approval of biosimilar and interchangeable products,” said Leah Christl, Ph.D., director of the Therapeutic Biologics and Biosimilars Staff in the FDA’s Center for Drug Evaluation and Research. “Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs.”

Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. A biosimilar is a biological product that is approved based on data showing that it is highly similar to a biological product already approved by the FDA (reference product) and has no clinically meaningful differences in terms of safety, purity and potency (i.e., safety and effectiveness) from the reference product, in addition to meeting other criteria specified by law.

The FDA’s approval of Retacrit is based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Retacrit is biosimilar to Epogen/Procrit. Retacrit has been approved as a biosimilar, not as an interchangeable product.

The most common side effects of epoetin alfa-treated patients in clinical studies of the reference product were high blood pressure, joint pain, muscle spasm, fever, dizziness, medical device malfunction, blood vessel blockage, respiratory infection, cough, rash, injection site irritation, nausea, vomiting, muscle pain, inflammation of the mouth and lips, weight decrease, reduction in white blood cells, bone pain, high blood sugar, insomnia, headache, depression, difficulty swallowing, low blood potassium, blood clots, itching, headache, injection site pain and chills.

Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drug’s uses and risks. In addition, as with Epogen/Procrit, Retacrit contains a Boxed Warning to alert health care professionals and patients about increased risks of death, heart problems, stroke and tumor growth or recurrence. Additional warnings include high blood pressure, seizures, a condition in which the bone marrow stops making red blood cells thus causing anemia, serious allergic reactions and severe skin reactions.

The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Everyday, worldwide, there are innumerable cases of emergency medical conditions. In Bangladesh population pressures, poverty, stress of modern life,…
Medical emergencies

Medical emergencies

What usually are the serious emergencies? There are a number of serious health condition requiring emergent attention. These medical conditions briefly…
Emergency medicine and critical care: A new horizon

Emergency medicine and critical care: A new horizon

Almost every hospital large or small, whether run privately or by Govt. has a designated area culled "JORURI BIVAG" or Emergency Room. Large…
Emergency management of convulsions in children

Emergency management of convulsions in children

Febrile convulsions Diagnosis based on presence of fever, short duration and no clinical evidence of CNS pathology. Clinical features The commonest cause…
Emergency risk management for health

Emergency risk management for health

Emergencies and disasters often result in significant impacts on people’s health, including the loss of many lives. Every new threat reveals the…
5 Reasons people who are suicidal don't reach out for help

5 Reasons people who are suicidal don't reach out for help

 Toni White   Though there are hundreds of thousands of people who die by suicide every year, it feels like there has been a wave of celebrity…
Geneticists make new discovery about how a baby's sex is determined

Geneticists make new discovery about how a baby's sex is determined

Medical researchers at Melbourne's Murdoch Children's Research Institute have made a new discovery about how a baby's sex is determined—it's…
Exactly why you keep waking up in the middle of the night, according to doctors

Exactly why you keep waking up in the middle of the night, according to doctors

 Alice Oglethorpe, Kate Bayless  It’s 2 a.m. and you’re wide awake. Again. What’s the deal? First, understand that waking…
Research Findings Dissemination Conference on Tobacco Control held in Bangladesh

Research Findings Dissemination Conference on Tobacco Control held in Bangladesh

Bangladesh Center for Communication Programs (BCCP) and Bangladesh Tobacco Control Research Network (BTCRN) in collaboration with the Institute for Global…
Some E-Cig liquids contain erectile dysfunction drugs: FDA

Some E-Cig liquids contain erectile dysfunction drugs: FDA

Consumers should not use two e-cigarette liquids that contain erectile dysfunction drugs because they may pose health risks, the U.S. Food and Drug Administration…
FDA approves Dextenza (dexamethasone ophthalmic insert) for the treatment of ocular pain following ophthalmic surgery

FDA approves Dextenza (dexamethasone ophthalmic insert) for the treatment of ocular pain following ophthalmic surgery

Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting